8-K: PepGen reports Phase 2 DM1 5 mg/kg safety, biomarker data

PepGen posted topline results from the lowest-dose 5 mg/kg Phase 2 FREEDOM2-DM1 cohort showing clean safety, modest mean splicing vs placebo but stronger effect excluding one outlier, vHOT improvement trends, and maintained guidance for 10 mg/kg data in 2H 2026 with cash runway into 2H 2027.

Summary

• Released topline results from the 5 mg/kg multiple-ascending dose (MAD) cohort (n=8; randomized 6:2) of the Phase 2 FREEDOM2-DM1 trial; data cutoff March 4, 2026.
• Safety profile was favorable: no serious adverse events (SAEs); all related treatment-emergent adverse events (TEAEs) were mild; most common TEAE was nausea; no renal TEAEs; no evidence of cumulative toxicity; no treatment-related discontinuations.
• Splicing biomarker: mean splicing correction of 7.3% in PGN-EDODM1-treated patients (n=6) versus 6.8% in placebo (n=2); excluding one outlier patient who worsened by 70.8%, mean splicing correction was 22.9% (n=5).
• vHOT (myotonia): middle finger vHOT showed a positive trend in the treatment group versus worsening in placebo; both groups returned to baseline by Week 16.
• Functional endpoints: no meaningful improvements observed in 10-meter walk/run test or handgrip strength at 5 mg/kg.
• Muscle exposure: mean muscle tissue concentration of PGN-EDODM1 was 158 ng/g in 5 of 6 treated patients measured ~1 week after the fourth dose (one readout pending).
• Dose escalation: the 10 mg/kg MAD cohort is more than halfway enrolled (5 of 8 patients dosed with up to three doses); study design allows escalation to 12.5 mg/kg pending DSMB review.
• Open-label extension (OLE): 12 patients enrolled at 5 mg/kg, including 5 patients from FREEDOM2.
• Guidance: Company expects 10 mg/kg cohort clinical data in the second half of 2026 and has sufficient cash to fund operations into the second half of 2027.
• Regulatory designations: PGN-EDODM1 has U.S. FDA Orphan Drug and Fast Track designations and EMA Orphan Designation for DM1.
• Regulatory status: The U.S. FDA recently placed a partial clinical hold on FREEDOM2-DM1 (as disclosed in the investor presentation).
• Conference call scheduled for March 30, 2026 at 4:30 p.m. ET.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as modestly positive: safety is clean and dose escalation is progressing with adequate cash runway, but efficacy at 5 mg/kg is mixed and sensitive to an outlier while a partial clinical hold adds regulatory risk.

Positives

• Clean safety at 5 mg/kg: no SAEs, all related TEAEs mild, no renal TEAEs, and no cumulative toxicity reported.
• Biomarker signal strengthens when excluding one predefined outlier: mean splicing correction of 22.9% (n=5).
• vHOT showed a favorable trend versus placebo at the lowest dose, suggesting dose-responsive potential.
• Muscle tissue exposure achieved (mean 158 ng/g ~1 week post-fourth dose in 5 of 6 treated patients), supporting target engagement.
• 10 mg/kg cohort dosing underway (5 of 8 patients dosed), with data expected in 2H 2026; protocol allows escalation to 12.5 mg/kg.
• Cash runway expected to fund operations into 2H 2027, reducing near-term financing risk.
• Regulatory tailwinds: FDA Orphan Drug and Fast Track designations; EMA Orphan Designation for PGN-EDODM1.

Negatives

• Overall mean splicing correction at 5 mg/kg (7.3%) was only marginally higher than placebo (6.8%), with results highly sensitive to a single outlier (−70.8%).
• No meaningful improvements observed in 10-meter walk/run test or handgrip strength at the 5 mg/kg starting dose.
• vHOT gains were not durable through Week 16, with both groups returning to baseline.
• Small cohort size (n=8; treated n=6, placebo n=2) limits statistical power and interpretability.
• The U.S. FDA recently placed a partial clinical hold on FREEDOM2-DM1, introducing regulatory uncertainty.
• One muscle concentration readout remained pending at cutoff, and broader pharmacokinetic/pharmacodynamic relationships are still being established.

Risks

• Potential delays or failure to initiate or complete ongoing and planned development activities for PGN-EDODM1, including FREEDOM2-DM1.
• Challenges enrolling patients in clinical trials, including FREEDOM2.
• Clinical and preclinical interpretations may be incorrect, and anticipated levels of therapeutic activity may not be observed.
• PGN-EDODM1 may not demonstrate safety or efficacy in clinical trials.
• Adverse regulatory outcomes, including delays in review, clearance to proceed, approval, or release of the partial clinical hold, as well as feedback requiring program modifications.
• Changes in regulatory frameworks outside the company’s control.
• Unexpected increases in development expenses or other events that adversely impact financial resources and cash runway.
• Dependence on third parties for manufacturing, research, and preclinical/clinical testing.
• Intellectual property risks, including the ability to obtain, maintain, protect, and enforce patents against third-party challenges.

Future Outlook

Management plans to complete dosing and report clinical data from the 10 mg/kg MAD cohort in the second half of 2026, continue the open-label extension at 5 mg/kg, and pursue the planned escalation pathway (up to 12.5 mg/kg) pending safety review, with sufficient cash expected to fund operations into 2H 2027.

Management Comments

• EVP R&D Paul Streck highlighted favorable safety and tolerability and positive trends in splicing and vHOT at 5 mg/kg, characterizing the results as supportive of ongoing dosing in the 10 mg/kg cohort.
• Management stated the 10 mg/kg multiple dose cohort is more than halfway enrolled and remains on track to read out in 2H 2026.

Industry Context

StockSavvy.ai notes that DM1 remains a competitive RNA-therapeutics space with Avidity Biosciences (AOC 1001) and Dyne Therapeutics (DYNE-101) advancing programs that have shown biomarker and early functional signals; PepGen’s clean safety and dose-escalation path are in line with peers, but the small, outlier-sensitive biomarker effect at 5 mg/kg underscores the importance of higher-dose, multi-dose data to assess competitiveness.

Comparison to Industry Standards

• Early-phase neuromuscular RNA programs typically prioritize clean safety and biomarker validation before functional gains; PepGen’s 5 mg/kg MAD results align with this pattern, similar to initial low-dose cohorts seen in Avidity’s AOC 1001 and Dyne’s DYNE-101 DM1 studies.
• Competitors have reported more robust biomarker and myotonia improvements at higher doses and/or after multiple doses; PepGen’s pending 10 mg/kg multi-dose readout in 2H 2026 will be the more appropriate benchmark for head-to-head relevance.
• Regulatory designations (Orphan/Fast Track) mirror peers in rare neuromuscular indications, helping expedite development timelines if efficacy strengthens at higher doses.

Stakeholder Impact

• Shareholders: Near-term catalyst preserved with 10 mg/kg data in 2H 2026; however, mixed low-dose efficacy and a partial clinical hold elevate uncertainty.
• Patients: Favorable safety and early biomarker trends support continued development; no functional benefit yet at 5 mg/kg.
• Employees/Clinical partners: Continued execution on Phase 2 and OLE programs; operational visibility supported by cash runway into 2H 2027.
• Regulators: Partial clinical hold indicates ongoing regulatory engagement and potential for protocol modifications.
• Suppliers/Manufacturing partners: Continued reliance on third parties for manufacturing and testing per disclosed risks.

Next Steps

• Continue dosing and complete enrollment in the 10 mg/kg MAD cohort (n=8 total).
• Report clinical data from the 10 mg/kg MAD cohort in 2H 2026.
• Maintain and expand participation in the 5 mg/kg open-label extension (currently 12 patients).
• Pursue planned dose escalation up to 12.5 mg/kg pending DSMB recommendations.
• Engage investors via webcast and ongoing meetings using the updated presentation.

Key Dates

Recommendation

Maintain a hold pending higher-dose (10 mg/kg) multi-dose data in 2H 2026. Safety is encouraging and cash runway is solid, but efficacy at 5 mg/kg is modest and highly outlier-sensitive, and the partial clinical hold injects regulatory risk; risk/reward improves only with clear biomarker and functional gains at higher doses.

Keywords

PGN-EDODM1, PepGen, FREEDOM2-DM1, myotonic dystrophy type 1, DM1, splicing correction, vHOT, oligonucleotide therapy, EDO platform, cell-penetrating peptides, DMPK, MBNL1, Phase 2, multiple ascending dose, Orphan Drug, Fast Track, EMA Orphan, partial clinical hold, cash runway